AI This Week: NVIDIA’s Record Revenue, Elon’s Data Centers in Space & Gemini 3’s Insane Performance w/ Salim Ismail, Dave Blundin & Alexander Wissner-Gross | EP #210

What It Covers

NVIDIA reports $57 billion quarterly revenue with 62% year-over-year growth as AI infrastructure buildout accelerates. Discussion covers data center expansion, space-based compute plans, humanoid robotics progress, energy constraints, and breakthrough developments in longevity science and autonomous delivery systems.

Key Questions Answered

• •NVIDIA Market Position: NVIDIA functions as central bank for AI, minting compute currency that all competitors must purchase. Company maintains pricing power through continuous architectural improvements offering 2-10x performance gains, with quarterly revenues jumping from $57 billion to projected $65 billion despite halfway point in chip optimization journey for neural networks.
• •Space-Based Computing Economics: Elon Musk plans 100 gigawatts per year of solar-powered AI satellites in orbit, equivalent to 25% of total US electricity consumption. Space offers 6x energy density versus ground-based systems, with radiative cooling to 3 Kelvin cosmic microwave background solving thermal challenges. Timeline: operational within 10 years, potentially scaling to 100 terawatts annually using lunar mass drivers.
• •Humanoid Robot Training Data: Unitree and Sunday Robotics deploy 500 memory developers wearing hand-tracking gloves that record daily human activities, creating largest robotic dexterity dataset. Vision-language-action foundation models now enable programming robots through demonstration rather than code, eliminating months of Python development time and accelerating deployment across nuclear reactors, pipelines, and space construction.
• •Energy Production Gap: China produces 325 terawatts versus US 80 terawatts in new electricity generation, 4x advantage. US faces critical 2030-2035 gap between chip manufacturing acceleration and fusion plant deployment. Perovskite solar and small modular reactors using TRISO fuel offer interim solutions, but regulatory timelines remain 5+ years for bringing capacity online.
• •Epigenetic Age Reversal: Life Biosciences enters 2026 human trials using adeno-associated virus delivery of OSK genes for partial epigenetic reprogramming. Initial focus targets eye conditions like glaucoma, with demonstrated age reversal in mice and monkeys. Technology addresses root cause aging rather than specific diseases, potentially expanding to liver and systemic applications if successful.